Tracked deals
6
6 tracked deals across 2020-2024.
Biotechnology Buyers & Acquisitions in Missouri
Buyer mix
Strategic-led
4 strategic · 2 pe
Top trend
Volume peaked in 2023
2 tracked deals announced in 2023.
Buyer Snapshot
Top Buyers
Illustrative buyers pulled from tracked transactions on this page. This table is capped and intentionally non-exhaustive.
| Buyer | # Deals | Focus | Type |
|---|---|---|---|
| Ampersand Capital Partners | 1 | Middle-market private equity firm focused on growth-orien... | PE |
| Bruker Corporation | 1 | Developer and manufacturer of high-performance scientific... | Strategic |
| Invaio Sciences | 1 | Ag-biotechnology company developing AI-enabled discovery ... | Strategic |
| Molecular Designs | 1 | Developer and manufacturer of multiplex PCR assays, compl... | Strategic |
| Paine Schwartz Partners (Paine Schwartz Food Chain Fund VI) | 1 | Private equity firm focused on sustainable food chain and... | PE |
| Valo Health | 1 | AI-driven drug discovery and development company using hu... | Strategic |
Acquisition Volume in Biotechnology in Missouri by Year
Last 4 years
Supporting Data
Recent Transactions
-
September 25, 2024
- Buyer
- Molecular Designs
- Target
- Lamda Biotech
- Industry
- Biotechnology
- Location
- Missouri, United States
- Type
- Buyout
Molecular Designs, a Birmingham-based provider of PCR assays and related reagents and equipment, has acquired Lamda Biotech, a St. Louis provider of molecular biology research products and kits. The deal will expand Molecular Designs’ product portfolio and manufacturing capacity while broadening access to academic research and pharmaceutical customers and strengthening R&D and technical talent.
-
December 7, 2023
- Buyer
- Invaio Sciences
- Target
- Peptyde Bio
- Seller
- Danforth Technology Company, Donald Danforth Plant Science Center
- Industry
- Biotechnology
- Location
- Missouri, United States
- Type
- Buyout
Invaio Sciences has acquired Peptyde Bio, a Danforth Technology Company spinout that discovers and designs antimicrobial peptides for crop protection. The deal brings Peptyde Bio’s peptide discovery platform and IP into Invaio’s AI-enabled discovery engine and biological delivery systems to accelerate nature-positive crop protection solutions.
-
- Buyer
- Paine Schwartz Partners (Paine Schwartz Food Chain Fund VI)
- Target
- Elemental Enzymes
- Industry
- Biotechnology
- Location
- Missouri, United States
- Type
- Growth capital
Paine Schwartz Partners (via Paine Schwartz Food Chain Fund VI) completed a strategic growth investment in Elemental Enzymes, a St. Louis-based developer of naturally occurring enzymes and biochemicals for commercial agriculture. Financial terms were not disclosed; the Elemental Enzymes management team will remain in place and will work with Paine Schwartz to expand R&D, launch new products, and enter new markets.
-
November 10, 2021
- Buyer
- Ampersand Capital Partners
- Target
- Leinco Technologies
- Industry
- Biotechnology
- Location
- Missouri, United States
- Type
- Recapitalization
Ampersand Capital Partners has completed a majority recapitalization of Leinco Technologies, a specialty manufacturer of life-science reagents and custom development services based near St. Louis, Missouri. The growth equity investment will fund expanded manufacturing capacity, broaden scientific capabilities and product offerings, and support Leinco's commercial and geographic expansion while leadership including founder Pat Leinert Sr. remain involved.
-
July 27, 2021
- Buyer
- Valo Health
- Target
- Courier Therapeutics
- Industry
- Biotechnology
- Location
- Missouri, United States
- Type
- Buyout
Valo Health has acquired Courier Therapeutics, a biotechnology company founded at Washington University in St. Louis that developed a protein therapeutics platform and the tumor-targeting candidate OPL-0101. The acquisition extends Valo’s Opal Computational Platform into protein therapeutics and is expected to broaden Valo’s modalities and capabilities across oncology and other therapeutic areas; the deal includes an upfront payment and milestone-based consideration.
-
September 11, 2020
- Buyer
- Bruker Corporation
- Target
- Canopy Biosciences, LLC
- Seller
- Ampersand Capital Partners
- Industry
- Biotechnology
- Location
- Missouri, United States
- Type
- Buyout
Bruker Corporation has acquired Canopy Biosciences, LLC to strengthen its targeted multi-omics and high-plex biomarker imaging capabilities, adding Canopy's ChipCytometry platform and multi-omics services. Financial terms were not disclosed; Ampersand Capital Partners was identified as Canopy's lead investor.
Build a buyer list for your Biotechnology deal
Find buyers actively acquiring biotechnology companies.
Related Acquisition Pages
Biotechnology Buyers & Acquisitions
Biotechnology Buyers & Acquisitions in Canada
Private Equity-Backed Biotechnology Buyers
Biotechnology Acquisitions in 2024
Biotechnology Acquisitions in 2023
Biotechnology Acquisitions in 2021
Biotechnology Acquisitions in 2020
Acquisitions in Missouri
Private Equity-Backed Acquisitions in Missouri
Acquisitions in Missouri in 2024
Acquisitions in Missouri in 2023
Acquisitions in Missouri in 2021